For decades, the evidence has been clear. Applying a warm compress to the perineum during the second stage of labour can reduce severe tearing by up to half [Perplexity Sonar Pro Brief]. The intervention is recommended in clinical guidelines, but it is rarely delivered consistently. It requires a midwife to hold a heated pad in place, often for an hour or more, in a delivery room where staffing is already stretched thin. The gap between what works in a study and what happens at the bedside is a classic, and painful, problem in maternal health.
A new UK startup, Peripear, is betting it can close that gap with hardware. Founded in early 2024 by NHS GP Dr. Verity Biggs, the company is developing a single-use, wearable device that adheres to the perineum. It delivers controlled therapeutic warmth and moisture automatically, aiming to standardize the warm compress intervention without adding to a clinician's workload [Perplexity Sonar Pro Brief]. The company recently closed a £1.2 million (approximately $1.5 million) pre-seed round led by Playfair Capital, with participation from Zinc VC, SyndicateRoom, and Hermesa [Playfair Capital, Unknown] [Angel Investment Network, 2024].
From clinical guideline to commercial device
The product concept is a direct translation of an existing best practice. Peripear's device is designed to be stretchable and non-invasive, maintaining a temperature of at least 38°C throughout crowning to gently support tissue and encourage natural stretching [Perplexity Sonar Pro Brief]. Once positioned, it is hands-free, requiring no further action from the midwife. This is the core of the company's wedge: turning a manual, staff-dependent procedure into a scalable, standardized product.
Early versions are described as single-use and heat-applying, not yet classified as a formal medical device [PreSeed Now, June 2024]. The company has a roadmap that envisions a future, reusable version that could be used from late pregnancy through early feeding. For now, the focus is on proving the initial concept in a clinical setting and navigating the regulatory pathway to become a certified medical device for sale to hospitals.
The founder's bedside view
The venture is led by Dr. Verity Biggs, a practicing GP and menopause specialist in the UK's National Health Service [LinkedIn, Unknown]. Her clinical perspective is central to the company's patient-centered framing. In early fundraising materials, she emphasized the mission to transform childbirth experiences and reduce a major source of maternal trauma [Angel Investment Network, 2024]. The company's website notes she teamed up with a collaborator named Evi to create the solution, though the specific roles beyond Dr. Biggs as CEO are not detailed in public sources [peri-pear.com, Unknown].
The backing from Playfair Capital, a London-based pre-seed firm known for its technical diligence, provides a signal of early venture confidence. The round reportedly built upon an earlier commitment of £800k from other investors before Playfair agreed to lead a larger raise [Medium, Unknown].
The market and the model
Peripear operates on a B2B model, with hospital labour and delivery units as the primary customer [Perplexity Sonar Pro Brief]. The value proposition is framed for both the patient and the healthcare system. For the birthing person, the goal is a less traumatic birth with fewer severe tears, minimized need for suturing, and a faster recovery. For the hospital, the device represents a potential tool to improve outcomes metrics and, by automating a manual task, alleviate pressure on midwifery teams [Health Innovation Network, Unknown].
The company has not yet publicly named any pilot hospital customers or clinical partners, placing it firmly in the pre-revenue, pre-market stage of development. Its immediate milestones will involve gathering clinical validation data and engaging with regulatory bodies like the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
Navigating the road to the delivery room
The ambition is significant, but the path is lined with the steep challenges inherent to novel medical hardware. Peripear must clear several high bars that have stalled many medtech startups.
- Clinical validation. While the underlying warm compress method is evidence-based, Peripear's specific device must prove its safety and efficacy in formal studies. These trials are costly and time-consuming.
- Regulatory classification. Achieving medical device status, likely as a Class I or II device in Europe, requires a rigorous quality management system and conformity assessment. The timeline and resource drain are non-trivial for a small team.
- Hospital procurement. Even with a regulatory green light, selling into NHS trusts or other hospital systems involves long sales cycles and competition for capital budgets. Demonstrating a clear return on investment, whether in better outcomes or staff time savings, will be critical.
- Manufacturing and cost. Developing a reliable, cost-effective single-use device that can be produced at scale presents its own engineering and supply chain hurdles. The unit economics must work within the constraints of hospital purchasing.
The company's most plausible answer to these risks lies in its focused simplicity. By targeting a single, well-defined procedure with strong existing evidence, Peripear may avoid the complexity of a multi-indication platform. The hands-free design directly addresses the adoption barrier of staff time. If the team can execute a lean initial pilot to generate promising data, it could build the momentum needed for a seed round targeted for 2027, as previously indicated [Angel Investment Network, 2024].
A quiet revolution in maternal care
The condition Peripear is tackling, obstetric perineal trauma, is remarkably common yet historically under-prioritized in medical device innovation. Up to 85% of women experience some degree of tearing during vaginal birth, with severe tears affecting between 3% and 6% of first-time mothers in the UK. These injuries can lead to significant long-term complications, including chronic pain, sexual dysfunction, and anal incontinence, profoundly impacting quality of life.
The current standard of care is reactive rather than preventive. Midwives are trained in perineal protection techniques, but the consistent application of warm compresses is often logistically impractical. When tears occur, they are repaired surgically, a process that itself carries risks and requires recovery. Episiotomies,surgical cuts made to enlarge the vaginal opening,are sometimes performed prophylactically, though evidence for their universal benefit is mixed. For severe tears, the physical and psychological aftermath can extend for months or years, representing a silent burden for millions.
Peripear's bet is that a small, simple device, born from a clinician's frustration with the status quo, can make a preventive, evidence-based intervention as routine as a fetal monitor. The next twelve months will be about moving from prototype to pilot, turning venture confidence into clinical data. For a field where progress is often measured in incremental guideline updates, that alone would be a notable step forward.
Sources
- [Perplexity Sonar Pro Brief, Unknown] Web-grounded research brief on Peripear's product and market
- [Playfair Capital, Unknown] Playfair Capital lead investor information
- [Angel Investment Network, 2024] Behind the Raise: Peripear Revolutionises Labour with New Device | https://www.angelinvestmentnetwork.net/behind-the-raise-peripear/
- [PreSeed Now, June 2024] PeriPear wants to start a revolution in the delivery room | https://preseednow.com/p/peripear
- [LinkedIn, Unknown] Dr Verity Biggs professional profile
- [peri-pear.com, Unknown] Peripear company website
- [Health Innovation Network, Unknown] NHS innovation body profile of Peripear
- [Medium, Unknown] The Full Story: Raising a £2m pre-seed for my Startup! | https://medium.com/@Jonny_Plein/the-full-story-raising-a-2m-pre-seed-for-my-startup-7dc3edeb0742